title: Hodgkin's Lymphoma in Older Patients: an Orphan Disease?
abstract: Hodgkin Lymphoma HL can be cured in the large majority of younger patients, but prognosis for older patients, especially those with advanced-stage disease, has not improved substantially. The percentage of HL patients aged over 60 ranges between 15% and 35%. A minority of them is enrolled into clinical trials. HL in the elderly have some specificities: more frequent male sex, B-symptoms, advanced stage, sub diaphragmatic presentation, higher percentage of mixed cellularity, up to 50% of advanced cases associated to EBV. Very old age (>70) and comorbidities are factor of further worsening prognosis. Like in younger patients, ABVD is the most used protocol, but treatment outcome remains much inferior with more frequent, severe and sometimes specific toxicities. Few prospective studies with specific protocols are available. The main data have been published by the Italian Lymphoma Group with the VEPEMB schedule and the German Hodgkin Study Group with the PVAG regimen. Recently, the Scotland and Newcastle Lymphoma Study Group published the SHIELD program associating a prospective phase 2 trial with VEPEMB and a prospective registration of others patients. Patients over 60y with early-stage disease received three cycles plus radiotherapy and had 81% of 3-year overall survival (OS). Those with advanced-stage disease received six cycles, with 3-year OS of 66%. The role of geriatric and comorbidity assessment in the treatment's choice for HL in the elderly is a major challenge. The combination of loss of activities of daily living combined with the age stratification more or less 70y has been shown as a simple and effective survival model. Hopes come from promising new agents like brentuximab-vedotin (BV) a novel antibody-drug conjugate. The use of TEP to adapt the combination of chemotherapy and radiotherapy according to the metabolic response could also be way for prospective studies.
authors.affiliation: Haematology Department; Centre Antoine-Lacassagne, 33 Avenue de Valombrose, 06189 Nice cedex 2, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Thyss
authors.affiliation: Haematology Department; Centre Antoine-Lacassagne, 33 Avenue de Valombrose, 06189 Nice cedex 2, France.
authors.forename: Esma
authors.initials: E
authors.lastname: Saada
authors.affiliation: Haematology Department; Centre Antoine-Lacassagne, 33 Avenue de Valombrose, 06189 Nice cedex 2, France.
authors.forename: Lauris
authors.initials: L
authors.lastname: Gastaud
authors.affiliation: Haematology Department; Centre Antoine-Lacassagne, 33 Avenue de Valombrose, 06189 Nice cedex 2, France.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Peyrade
authors.affiliation: Haematology Department; Centre Antoine-Lacassagne, 33 Avenue de Valombrose, 06189 Nice cedex 2, France.
authors.forename: Daniel
authors.initials: D
authors.lastname: Re